Atezolizumab Provides No Benefit in Head and Neck Cancer
Atezolizumab after multi-modal definitive treatment did not improve outcomes in patients with locally advanced head and neck cancer.
Related Articles
Certain Early-Onset Cancers Are on the Rise in the US
The incidence and death rates for early-onset cancers varied by age group and cancer type.
ASTCT EBMT Relapse Conference
The American Society for Transplantation and Cellular Therapy is an international professional membership association of more than 3,900 physicians, investigators and other health care professionals…
ZUMA-12 Suggests Axi-Cel May Be Curative in First-Line, High-Risk LBCL | Blood Cancers Today
The safety results from this phase 2 trial were also consistent with those observed in other studies.
SGO ConnectEd |
Missed out? Check out the latest round-up of SGO releases, on demand! Check out the latest SGO Taskforce for Board Certification Support content, highlighted below.…
Interplay between iron metabolism, inflammation, and EPO-ERFE-hepcidin axis in RDEB-associated chronic anemia
Key PointsElevated hepcidin in patients with RDEB with anemia was mainly linked to high ferritin and a history of IV iron infusions/blood transfusion.Among
What Is Cancer?
Explanations about what cancer is, how cancer cells differ from normal cells, and genetic changes that cause cancer to grow and spread.
Cellular and biochemical heterogeneity contributes to the phenotypic diversity of transfusion-dependent β-thalassemia
Key PointsRed cells in TDT exhibit unique ultrastructural distortions, susceptibility to oxidants, and reduced proteasome activity.The wide heterogeneity i
VJOncology – The video journal of oncology
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
VJHemOnc – The video journal of hematological oncology
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
Zoldonrasib Shows Encouraging Early Antitumor Activity in KRAS G12D–Mutated NSCLC
Zoldonrasib demonstrates early promise in patients with KRAS G12D–mutated non–small cell lung cancer.
